Targets › PP65
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on PP65, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Florida | pp65 RNA loaded lipid particles (DP1) mRNA vaccine encoding pp65 antigen in lipid nanoparticles | PP65 | Phase 1 | Recurrent Glioblastoma | Dec 2026 |
Recurrent Glioblastoma (2)
protein or peptide (1)
University of Florida (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.